Permax Recall: Four Years Later

In March of 2007, the U.S. Food and Drug Administration (FDA) announced a Permax recall. Four years later, new cases of Permax side effects are still being reported and many Permax victims remain uncompensated for their suffering.

Current studies have revealed Permax heart valve disease in around one-fourth of Parkinson’s patients who have taken Permax over an extended period of time.

Permax Valvulopathy (valve injuries) first came to the attention of the Federal Drug Administration (FDA) in 2002. Permax was approved by the FDA in 1988. Prior to the Permax recall, the FDA added a black box warning regarding the risk of serious heart valve damage.

Permax side effects including heart valve damage were revealed in the studies published in the New England Journal of Medicine (NEJM). High rates of valve leakage were found in up to 20% of patients prescribed Permax. Dr. Robert Temple, the associate director for medical policy at the Center for Drug Evaluation and Research, stated that Permax (Peroglide) was linked with a fivefold increase in regurgitation of the mitral, atrial, or tricuspid valves compared with the general population. The side effects revealed in these studies were further evidence of the ongoing problems leading to the Permax recall.

Permax was released in 1989 after being developed by Eli Lilly. Over 500,000 people have taken Permax since 1989 to treat Parkinson’s and RLS. Two European studies were conducted in Britain and Italy. In the Italian study, of the 155 people who had taken Permax, 23.4% of them developed Permax heart problems. The British study involved 11,417 people who were taking the drug. Patients in the British study were 37 times more probable to develop Permax heart damage problems. Serious Permax heart valve disease has also been reported by the Mayo Clinic in patients who took the drug and were later diagnosed with heart problems.

To discuss your potential Permax claim, contact the drug recall lawyers at today. You have legal options!

Bookmark and Share

Comments are closed.